0.0949
price down icon19.37%   -0.0228
after-market 시간 외 거래: .09 -0.0049 -5.16%
loading
전일 마감가:
$0.1177
열려 있는:
$0.112
하루 거래량:
2.31M
Relative Volume:
2.32
시가총액:
$6.52M
수익:
$202.00K
순이익/손실:
$-28.96M
주가수익비율:
-0.1582
EPS:
-0.6
순현금흐름:
$-21.85M
1주 성능:
-21.57%
1개월 성능:
-23.10%
6개월 성능:
-63.98%
1년 성능:
-82.09%
1일 변동 폭
Value
$0.0633
$0.1179
1주일 범위
Value
$0.0633
$0.1347
52주 변동 폭
Value
$0.0633
$0.62

AIM ImmunoTech Inc Stock (AIM) Company Profile

Name
명칭
AIM ImmunoTech Inc
Name
전화
352 448 7797
Name
주소
2117 SW Highway 484, Ocala, FL
Name
직원
24
Name
트위터
@AIMImmuno
Name
다음 수익 날짜
2024-12-15
Name
최신 SEC 제출 서류
Name
AIM's Discussions on Twitter

AIM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
AIM
AIM ImmunoTech Inc
0.0949 6.52M 202.00K -28.96M -21.85M -0.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스

pulisher
06:18 AM

Aim Immunotech’s COO Peter Rodino III acquires shares for $43 - Investing.com

06:18 AM
pulisher
05:59 AM

AIM ImmunoTech (AIM) Faces Delisting from NYSE American - GuruFocus

05:59 AM
pulisher
05:54 AM

AIM ImmunoTech faces NYSE American delisting over low stock price - Investing.com

05:54 AM
pulisher
05:22 AM

AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN

05:22 AM
pulisher
04:48 AM

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewswire

04:48 AM
pulisher
04:45 AM

NYSE American Suspends AIM ImmunoTech Trading: Company Fighting Delisting Notice - Stock Titan

04:45 AM
pulisher
04:25 AM

NYSE American To Commence Delisting Proceedings Against Aim Immunotech Inc - MarketScreener

04:25 AM
pulisher
04:05 AM

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire

04:05 AM
pulisher
09:53 AM

Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - Benzinga

09:53 AM
pulisher
Apr 03, 2025

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript - Insider Monkey

Apr 03, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strat - GuruFocus

Apr 02, 2025
pulisher
Apr 01, 2025

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire

Apr 01, 2025
pulisher
Apr 01, 2025

AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener

Apr 01, 2025
pulisher
Mar 31, 2025

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 31, 2025
pulisher
Mar 28, 2025

Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings Preview For AIM ImmunoTech - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Inc. (AIM) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan

Mar 27, 2025
pulisher
Mar 19, 2025

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World

Mar 18, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan

Mar 11, 2025
pulisher
Mar 06, 2025

Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News

Mar 06, 2025
pulisher
Mar 05, 2025

Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India

Mar 05, 2025
pulisher
Mar 04, 2025

Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock By Investing.com - Investing.com Australia

Mar 04, 2025
pulisher
Mar 04, 2025

Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable

Mar 04, 2025
pulisher
Feb 28, 2025

AIM ImmunoTech appoints Chemerow as an Independent Director - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

AIM ImmunoTech Inc. Appoints Principal Investigator for Clinical Study Combining Ampligen and AstraZeneca's FluMist for Influenza Vaccine Development - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

AIM announces Paul Goepfert, MD, as the principal - GlobeNewswire

Feb 28, 2025
pulisher
Feb 28, 2025

Could This $10M Avian Flu Vaccine Strategy Outperform Billion-Dollar mRNA Alternatives? - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

AIM ImmunoTech to Present at the Investor Summit in Philadelphia - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM' - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times

Feb 27, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Plans to Meet NYSE Compliance by 2026 Amid Cancer and Antiviral Drug Advances - HPBL

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Eyes a Resilient Comeback with Strategic Moves to Stay Afloat - Smartphone Magazine

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech gains NYSE compliance plan approval By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Biotech Trailblazer AIM ImmunoTech Charts a Resilient Path to Equity Compliance - Jomfruland.net

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech gains NYSE compliance plan approval - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Secures NYSE American Compliance Plan Approval – What It Means for Investors - HPBL

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Says NYSE American Accepts Plan to Regain Compliance -February 26, 2025 at 01:37 pm EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

AIM ImmunoTech Inc. Receives Approval from NYSE American for Compliance Plan with Listing Standards - Nasdaq

Feb 26, 2025

AIM ImmunoTech Inc (AIM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):